513 related articles for article (PubMed ID: 19828011)
1. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.
Fatourou EM; Koskinas JS
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1499-510. PubMed ID: 19828011
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
3. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
4. Cell-mediated immune responses to alpha-fetoprotein and other antigens in hepatocellular carcinoma.
Behboudi S; Boswell S; Williams R
Liver Int; 2010 Apr; 30(4):521-6. PubMed ID: 20040052
[TBL] [Abstract][Full Text] [Related]
5. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Sun K; Wang L; Zhang Y
Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
[TBL] [Abstract][Full Text] [Related]
7. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
Schmidt N; Neumann-Haefelin C; Thimme R
Dig Dis; 2012; 30(5):483-91. PubMed ID: 23108304
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Expert Rev Gastroenterol Hepatol; 2010 Jun; 4(3):345-53. PubMed ID: 20528121
[TBL] [Abstract][Full Text] [Related]
9. Immune responses in hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Dig Dis; 2010; 28(1):150-4. PubMed ID: 20460904
[TBL] [Abstract][Full Text] [Related]
10. Specific CD8(+ )T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination.
Zhang HG; Chen HS; Peng JR; Shang XY; Zhang J; Xing Q; Pang XW; Qin LL; Fei R; Mei MH; Leng XS; Chen WF
Cancer Immunol Immunother; 2007 Dec; 56(12):1945-54. PubMed ID: 17522859
[TBL] [Abstract][Full Text] [Related]
11. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation.
Zerbini A; Pilli M; Fagnoni F; Pelosi G; Pizzi MG; Schivazappa S; Laccabue D; Cavallo C; Schianchi C; Ferrari C; Missale G
J Immunother; 2008 Apr; 31(3):271-82. PubMed ID: 18317360
[TBL] [Abstract][Full Text] [Related]
12. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.
Zerbini A; Pilli M; Penna A; Pelosi G; Schianchi C; Molinari A; Schivazappa S; Zibera C; Fagnoni FF; Ferrari C; Missale G
Cancer Res; 2006 Jan; 66(2):1139-46. PubMed ID: 16424051
[TBL] [Abstract][Full Text] [Related]
13. Activation of dendritic cells by local ablation of hepatocellular carcinoma.
Ali MY; Grimm CF; Ritter M; Mohr L; Allgaier HP; Weth R; Bocher WO; Endrulat K; Blum HE; Geissler M
J Hepatol; 2005 Nov; 43(5):817-22. PubMed ID: 16087270
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice.
Zhang W; Liu J; Wu Y; Xiao F; Wang Y; Wang R; Yang H; Wang G; Yang J; Deng H; Li J; Wen Y; Wei Y
Biochem Biophys Res Commun; 2008 Nov; 376(1):10-4. PubMed ID: 18725206
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of hepatocellular carcinoma: is there a place for regulatory T-lymphocyte depletion?
Cany J; Tran L; Gauttier V; Judor JP; Vassaux G; Ferry N; Conchon S
Immunotherapy; 2011 Apr; 3(4 Suppl):32-4. PubMed ID: 21524167
[TBL] [Abstract][Full Text] [Related]
17. Potential of immunotherapy for hepatocellular carcinoma.
Breous E; Thimme R
J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
[TBL] [Abstract][Full Text] [Related]
18. [Perspectives on immunotherapy for hepatocellular carcinoma].
Schmidt N; Büttner N; Thimme R
Dtsch Med Wochenschr; 2013 Apr; 138(14):740-4. PubMed ID: 23533044
[TBL] [Abstract][Full Text] [Related]
19. Distinct tumour antigen-specific T-cell immune response profiles at different hepatocellular carcinoma stages.
Zang C; Zhao Y; Qin L; Liu G; Sun J; Li K; Zhao Y; Sheng S; Zhang H; He N; Zhao P; Wang Q; Li X; Peng Y; Dong T; Zhang Y
BMC Cancer; 2021 Sep; 21(1):1007. PubMed ID: 34496797
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.
Si S; Sun Y; Li Z; Ge W; Zhang X; Hu P; Huang Y; Chen G; Song H; Huang Y; Ma B; Li X; Sui Y
Gene Ther; 2006 Nov; 13(22):1603-10. PubMed ID: 16855617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
